Literature DB >> 22982378

The hepatic phosphatidylcholine transporter ABCB4 as modulator of glucose homeostasis.

Katrin Hochrath1, Marcin Krawczyk, Reinhild Goebel, Miriam Langhirt, Birgit Rathkolb, Kateryna Micklich, Jan Rozman, Marion Horsch, Johannes Beckers, Martin Klingenspor, Helmut Fuchs, Valérie Gailus-Durner, Eckhard Wolf, Monica Acalovschi, Dietrich A Volmer, Martin Hrabě de Angelis, Frank Lammert.   

Abstract

The hepatic phosphatidylcholine (PC) transporter ATP-binding cassette (ABC) B4 flops PC from hepatocytes into bile, and its dysfunction causes chronic cholestasis and fibrosis. Because a nuclear receptor-dependent PC pathway has been determined to exert antidiabetic effects, we now analyzed the role of ABCB4 in glucose metabolism. We bred congenic Abcb4-knockout (Abcb4(-/-)) mice on the fibrosis-susceptible BALB/cJ background. Knockout mice and wild-type controls were phenotyped by measuring plasma glucose concentrations, intraperitoneal glucose tolerance, hepatic RNA expression profiles, and liver histology. In addition, 4 procholestatic ABCB4 gene variants were correlated with blood glucose levels in 682 individuals from 2 independent European cohorts. Systemic glucose levels differ significantly between Abcb4(-/-) mice and wild-type controls, and knockout mice display improved glucose tolerance with significantly lower area under the curve values on intraperitoneal glucose challenge. Of note, hepatic expression of the antidiabetic nuclear receptor 5A2 (LRH-1) is induced consistently in Abcb4(-/-) mice, and its specific rare PC ligands are detected in liver by mass spectrometry imaging. In humans, serum glucose levels are associated significantly with the common ABCB4 variant c.711A>T. In summary, ABCB4 might play a critical role in glucose homeostasis in mice and humans. We speculate that the effects could be mediated via LRH-1-dependent PC pathways.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22982378     DOI: 10.1096/fj.12-209379

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  9 in total

1.  Genetic signatures in choline and 1-carbon metabolism are associated with the severity of hepatic steatosis.

Authors:  Karen D Corbin; Manal F Abdelmalek; Melanie D Spencer; Kerry-Ann da Costa; Joseph A Galanko; Wei Sha; Ayako Suzuki; Cynthia D Guy; Diana M Cardona; Alfonso Torquati; Anna Mae Diehl; Steven H Zeisel
Journal:  FASEB J       Date:  2013-01-04       Impact factor: 5.191

2.  Modeling hepatic osteodystrophy in Abcb4 deficient mice.

Authors:  Katrin Hochrath; Sabrina Ehnert; Cheryl L Ackert-Bicknell; Yvonne Lau; Andrea Schmid; Marcin Krawczyk; Jan G Hengstler; Jordanne Dunn; Kanishka Hiththetiya; Birgit Rathkolb; Kateryna Micklich; Wolfgang Hans; Helmut Fuchs; Valérie Gailus-Durner; Eckhard Wolf; Martin Hrabě de Angelis; Steven Dooley; Beverly Paigen; Britt Wildemann; Frank Lammert; Andreas K Nüssler
Journal:  Bone       Date:  2013-03-29       Impact factor: 4.398

Review 3.  Genetic Analysis of ABCB4 Mutations and Variants Related to the Pathogenesis and Pathophysiology of Low Phospholipid-Associated Cholelithiasis.

Authors:  Helen H Wang; Piero Portincasa; Min Liu; David Q-H Wang
Journal:  Genes (Basel)       Date:  2022-06-11       Impact factor: 4.141

4.  TLR4 Deficiency Protects against Hepatic Fibrosis and Diethylnitrosamine-Induced Pre-Carcinogenic Liver Injury in Fibrotic Liver.

Authors:  Susanne Nicole Weber; Annika Bohner; Dianne H Dapito; Robert F Schwabe; Frank Lammert
Journal:  PLoS One       Date:  2016-07-08       Impact factor: 3.240

5.  Effects of Liver Fibrosis Progression on Tissue Relaxation Times in Different Mouse Models Assessed by Ultrahigh Field Magnetic Resonance Imaging.

Authors:  Andreas Müller; Katrin Hochrath; Jonas Stroeder; Kanishka Hittatiya; Günther Schneider; Frank Lammert; Arno Buecker; Peter Fries
Journal:  Biomed Res Int       Date:  2017-01-18       Impact factor: 3.411

6.  TGF-β2 silencing to target biliary-derived liver diseases.

Authors:  Anne Dropmann; Steven Dooley; Bedair Dewidar; Seddik Hammad; Tatjana Dediulia; Julia Werle; Vanessa Hartwig; Shahrouz Ghafoory; Stefan Woelfl; Hanna Korhonen; Michel Janicot; Katja Wosikowski; Timo Itzel; Andreas Teufel; Detlef Schuppan; Ana Stojanovic; Adelheid Cerwenka; Stefanie Nittka; Albrecht Piiper; Timo Gaiser; Naiara Beraza; Malgorzata Milkiewicz; Piotr Milkiewicz; John G Brain; David E J Jones; Thomas S Weiss; Ulrich M Zanger; Matthias Ebert; Nadja M Meindl-Beinker
Journal:  Gut       Date:  2020-01-28       Impact factor: 23.059

7.  Experimental liver fibrosis research: update on animal models, legal issues and translational aspects.

Authors:  Christian Liedtke; Tom Luedde; Tilman Sauerbruch; David Scholten; Konrad Streetz; Frank Tacke; René Tolba; Christian Trautwein; Jonel Trebicka; Ralf Weiskirchen
Journal:  Fibrogenesis Tissue Repair       Date:  2013-10-01

8.  Deficiency of multidrug resistance 2 contributes to cell transformation through oxidative stress.

Authors:  Ali Tebbi; Florence Levillayer; Grégory Jouvion; Laurence Fiette; Guillaume Soubigou; Hugo Varet; Nesrine Boudjadja; Stefano Cairo; Kosuke Hashimoto; Ana Maria Suzuki; Piero Carninci; Annamaria Carissimo; Diego di Bernardo; Yu Wei
Journal:  Carcinogenesis       Date:  2015-11-05       Impact factor: 4.944

9.  Effects of blocking chemokine receptor CCR1 with BX471 in two models of fibrosis prevention and rescue in mice.

Authors:  Susanne N Weber; Irina Nowak; Frank Grünhage; Frank Lammert
Journal:  Biochem Biophys Rep       Date:  2021-07-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.